Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in Primary Immune Thrombocytopenia (ITP) Phase I/II Study
CTR20250549Phase 2Active
- Sponsor
- Affinity Biopharma
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ESG206 in immune thrombocytopenia (ITP), sponsored by Affinity Biopharma. Started Feb 2025; status: active.
02
Drugs
ESG206
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20250549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250549.